Vimarsana
Biggest News Aggregation in the World

Page 36 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey - Vimarsana News

BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, and Crossroads4Hope, A Network of Cancer Support

Zacks Investment Research Lowers BeiGene (NASDAQ:BGNE) to Sell - Vimarsana News

Zacks Investment Research Lowers BeiGene (NASDAQ:BGNE) to Sell

BeiGene (NASDAQ:BGNE – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is […]

BeiGene Reports China NMPA's Approval Of Tislelizumab - Vimarsana News

BeiGene Reports China NMPA's Approval Of Tislelizumab

BASEL (dpa-AFX) - BeiGene, Ltd. (BGNE) announced the China National Medical Products Administration or NMPA has granted approval to the company's anti-PD-1 antibody, tislelizumab, as a treatment

BeiGene: China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma - Vimarsana News

BeiGene: China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma

Tislelizumab is now approved for eight indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative

IRC Determines BRUKINSA (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia - Vimarsana News

IRC Determines BRUKINSA (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia

11.04.2022 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced results from the Phase 3 ALPINE trial showing BTK inhibitor BRUKINSA ... Seite 1